Long-term treatment of strabismus with Botox

Article

A long-term course of injections of botulinum toxin ("Botox") offers a viable treatment for complicated strabismus, according to study results published in the December 2008 issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus.

A long-term course of injections of botulinum toxin ("Botox") offers a viable treatment for complicated strabismus, according to study results published in the December 2008 issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus.

John P. Lee, FRCS, FRCP, FRCOphth of Moorfields Eye Hospital, London, UK and colleagues conducted a retrospective review to identify strabismic patients receiving a minimum of 25 botulinum toxin injections between November 1982 and January 2006, and compared treatment outcomes of this group with those receiving fewer injections.

The duration of treatment was 3–22 years, and the team found that there was no statistically significant difference in the complication rate of the 57 patients receiving ≥25 injections when compared with patients receiving fewer injections. The number of injections required decreased over time. Patients in the group receiving ≥25 injections were found to have a greater amount of previous operations and a lower level of binocularity.

Thus the team concluded that long-term botulinum toxin injection therapy is safe for the treatment of strabismus, and may be the most appropriate treatment course for the management of complicated strabismus, or those with either multiple previous operations or poor binocular potential.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.